Gulf Coast TX
Drug developer Lycia Therapeutics targets $938 million valuation in US IPO
Oct 20 (Reuters) -- Drug developer Lycia Therapeutics said on Tuesday it was targeting a valuation of up to $937.7 million in its US initial public offering, as biotech companies f…
